



(51) International Patent Classification:
C12Q 1/68 (2006.01)

(21) International Application Number:
PCT/US2014/064336

(22) International Filing Date:
6 November 2014 (06.11.2014)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
61/900,772 6 November 2013 (06.11.2013) US

(71) Applicant: **RAPTOR PHARMACEUTICALS INC.**
[US/US]; 7 Hamilton Landing, Suite 100, Novato, CA
94949 (US).

(72) Inventors: **RIOUX, Patrice**; 7 Hamilton Landing, Suite
100, Novato, CA 94949 (US). **ZANKEL, Todd, C.**; 6930
California Street, San Francisco, CA 94121 (US).

(74) Agent: **NEVILLE, Katherine, L.**; Marshall, Gerstein &
Borun LLP, 233 S. Wacker Drive, 6300 Willis Tower,
Chicago, IL 60606-6357 (US).

(81) Designated States (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

— *without international search report and to be republished upon receipt of that report (Rule 48.2(g))*

(54) Title: USE OF CYSTEAMINE AND DERIVATIVES THEREOF TO TREAT MITOCHONDRIAL DISEASES

(57) Abstract: The present disclosure is directed to methods for treating inherited or acquired mitochondrial disease using a cysteamine product, e.g., cysteamine or cystamine or derivatives thereof.



WO 2015/069888 A2